TL;DR
The engineered nanoparticle-in-capsule platform integrates HA-mediated surface functionalization with pH-triggered colonic release, offering a promising colon-directed oral delivery platform for 5-FU.
The developed chitosan-coated Eudragit® S100 nanoparticle system represents a promising platform for sustained, colon-targeted oral delivery of HSP and other poorly bioavailable bioactive compounds.
Proof of concept is provided that HA-CH-coated mesoporous silica nanoparticles enhance the in vitro anticancer activity of repurposed propranolol through encapsulation and controlled release, laying the foundation for future investigation of HA-mediated cellular targeting.
The developed pellet system, which encapsulates 5-ASA within GMO/LA-based liquid crystal nanoparticles, presents a highly promising platform for targeted drug delivery in the treatment of ulcerative colitis.
Lamotrigine-loaded chitosan-sodium alginate polymeric nanoparticle system optimized by BoxBehnken Design demonstrated improved release control, enhanced pharmacokinetic parameters, and superior anticonvulsant activity in vivo, supporting their potential as a sustained-release system for epilepsy management.
The study suggests the potential of CH-NLCs for improved oral delivery by formulating chitosan-coated AZM NLCs and optimizing using QbD approach.
Overall, the developed PLA:Gel core-shell nanofibers represent a promising biomaterial-based platform for dual drug delivery of hydrophobic and hydrophilic agents, offering controlled release and promising in vitro antiproliferative activity.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
